Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan 30:5:9.
doi: 10.1186/1479-5876-5-9.

CD8 apoptosis may be a predictor of T cell number normalization after immune reconstitution in HIV

Dorothy E Lewis  1 , Kimber L Gross, Martine M Diez, Maria L Martinez, Helen N Lukefahr, Claudia A Kozinetz, Roberto C Arduino
Affiliations

CD8 apoptosis may be a predictor of T cell number normalization after immune reconstitution in HIV

Dorothy E Lewis et al. J Transl Med. .

Abstract

Background: As part of the Houston Vanguard study, a subset of 10 patients randomized to receive IL-2 therapy were compared to 4 patients randomized to not receive IL-2, for markers of T cell activation and death during the first three cycles of IL-2. All patients were treated with combination antiretroviral therapy (ART) and were virally suppressed. The purpose of the study was to examine the role of CD8(+) T cell death in responses to ART and IL-2 therapy.

Methods: Lymphocytes were examined at Day 0, 5 and 30 days during three cycles of IL-2 therapy. CD25, CD38, HLA-DR expression and annexin (cell death) were examined on CD4 and CD8 subpopulations. Follow up studies examined CD4 levels and CD4:CD8 reconstitution after 6 years using both univariant and multivariate analyses.

Results: Human lymphocytes responded to IL-2 therapy by upregulation of CD25 on CD4(+) T cells, leading to an increase in CD4 cell counts. CD8(+) T cells did not increase CD25 expression, but upregulated activation antigens (CD38 and DR) and had increased death. At baseline, 7 of the 14 patients had high CD8+ T cell apoptosis (mean 17.0% +/- 6.0). We did an exploratory analysis of immune status after six years, and found that baseline CD8+ T cell apoptosis was correlated with CD4 cell count gain beginning two years post enrollment. Patients with low levels of CD8(+) T cell apoptosis at baseline (mean 2.2% +/- 2.1) had significantly higher CD4 cell counts and more normalized CD4:CD8 ratios than patients with high CD8(+) T cell apoptosis (mean CD4 cell counts 1,209 +/- 164 vs 754 +/- 320 cells/mm(3); CD4:CD8 ratios 1.55 vs. 0.70, respectively).

Conclusion: We postulate that CD8(+) T cell apoptosis may reflect inherent activation status, which continues in some patients even though viral replication is suppressed which influences the ability of CD4(+) T cells to rebound. Levels of CD8(+) T cell apoptosis may therefore be an independent predictor of immune status, which should be shown in a prospective study.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Increase in CD25 Expression on CD4+ T Cells 5 Days after IL-2 Therapy Initiation. Histogram of a representative response of CD4+ and CD8+ T cells to scIL-2. Shown are staining of CD4+ and CD8+ T cells with CD25 at Day 0 and after 5 days of self administered scIL-2. Only the CD4+T cells show an increase of CD25 after 5 days.
Figure 2
Figure 2
CD4+ T Cells Respond to IL-2 by Up-regulating CD25 Expression 5 Days after Every Cycle. a and b. IL-2 induces more CD25 expression on CD4+ T cells. Values are percentage of (a) CD4+ or (b) CD8+ T cells which express CD25. Representative low-dose recipient shown. Patient received scIL-2 on days 1–5, 65–69 and 121–125
Figure 3
Figure 3
Increase in CD38+DR+ CD8+ T Cells 5 Days after scIL-2 Therapy Initiation. Cytograms of CD38 and DR expression on CD8+ T cells during a single cycle of scIL-2. Both the percentage of CD38DRbright cells increases as well as the MFI of CD38 on the whole population. (CD38 MFI DAY 0 = 7.41, DAY 5 = 20.9, DAY 30 = 7.46)
Figure 4
Figure 4
Activation and death of CD8 T cells in a patient receiving three cycles of high dose scIL-2. Dying CD8+ T cells are activated. Values are percentage of CD8+ T cells that are CD38+ DRHi (diamonds) or that bind Annexin V (circles). Patient received 7.5 MIU scIL-2 on days 1–5, 57–61 and 114–118.
Figure 5
Figure 5
CD4:CD8 Ratios over Time in Low versus High CD8 Apoptosis Groups. The low baseline CD8+ T cell annexin group has a higher mean CD4:CD8 ratio after six years than high baseline CD8+ T cell annexin group. The results are the mean values of CD4:CD8 ratio ± SD. A repeated measures ANOVA indicated a statistically significant difference (p = 0.041).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. De Paoli P. Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects. Clin Diagn Lab Immunol. 2001;8:671–677. doi: 10.1128/CDLI.8.4.671-677.2001. - DOI - PMC - PubMed
    1. Marchetti G, Franzetti F, Gori A. Partial immune reconstitution of highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap? J Antimicrob Chemother. 2005;55:401–409. doi: 10.1093/jac/dkh557. - DOI - PubMed
    1. Sereti I, Anthony KB, Martinez-Wilson H, Lempicki R, Adelsberger J, Metcalf JA, Hallahan CW, Follmann D, Davey RT, Kovacs JA, Lane C. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood. 2004;104:775–780. doi: 10.1182/blood-2003-12-4355. - DOI - PubMed
    1. Kovacs JA, Lempicki RA, Sidorov I, Adelsberger JW, Sereti I, Sachau W, Nelly G, Metcalf JA, Davey RT, Falloon J, Polis MA, Tavel J, Stevens R, Lambert L, Hosack DA, Bosche M, Isaac HJ, Fox SD, Leitman S, Baseler MW, Masur H, Di Mascio M, Dimitrov DS, Lane HC. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest. 2005;115:2139–2148. doi: 10.1172/JCI23196. - DOI - PMC - PubMed
    1. Seriti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, Berg SC, Metcalf JA, Hahn BK, Shen JM, Powers A, Davey RT, Kovacs JA, Shevach EM, Lane HC. In vivo expansion of CD4+ CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest. 2005;115:1839–1847. doi: 10.1172/JCI24307. - DOI - PMC - PubMed

Publication types

MeSH terms